Skip to main content

Synendos Therapeutics awarded EU funding

| News

Synendos Therapeutics awarded EU funding

29.07.2019

Synendos Therapeutics AG with headquarters in Allschwil is benefiting from the financial support for which small and medium-sized enterprises can apply within the framework of Horizon 2020, a program launched by the EU. The pharma company is also supported by the start-up accelerator BaseLaunch.

Andrea Chicca, Co-founder & CEO of Synendos Therapeutics (img. Mathias Mangold)

Synendos Therapeutics AG, a company headquartered in Switzerland Innovation Park Basel Area, is developing a new class of molecules. The pharma firm intends to use these to treat anxiety and other stress related disorders. The accelerator BaseLaunch has already included the start-up in Phase II of the program. BaseLaunch is handled by BaselArea.swiss, which also manages the Switzerland Innovation Park Basel Area. Now, the European Union (EU) has also rewarded the innovative approach pursued by Synendos Therapeutics, as outlined by an article from startupticker.ch.

Synendos has been chosen among a total of 22 Swiss start-ups for the first phase of the SME program linked to Horizon 2020. This entails financial support in the form of a grant worth 50,000 euros. Moreover, these companies can then also opt to apply for Phase II, in which participating companies can receive grants of between 0.5 million and 2.5 million euros in order to launch pilot projects or grow their business.

ABBA Therapeutics from Basel also made it into the first phase of the program. The company develops antibodies aimed at helping to fight cancer. With its approach, it has also already achieved Phase I of BaseLaunch.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.